Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Peloton

Gap Inc

The Federal Reserve is set to make its next move shortly, and it could send a shock through the market. With already high interest rates, a sticky inflation problem and an uncertain economic outlook, many investors are taking a cautious approach for the rest of 2023.

3 Stocks to Avoid Like the Plague Right Now: MRNA, GPS, PTON

ANN ARBOR, Mich.--(BUSINESS WIRE)--CareEvolution is excited to announce that enrollment through its clinical research platform, MyDataHelps, has opened for a groundbreaking study on cytomegalovirus (CMV) transmission within childcare settings to meet participants in their existing day-to-day environments. The CMV Transmission and Immune Tracking (CMV TransmIT) study is a collaborative effort between UMass Chan Medical School and Moderna. Unique in its approach, this study pioneers a digital app.

UMass Chan Medical School and Moderna launch CMV TransmIT—a CareEvolution MyDataHelps-powered study for cytomegalovirus (CMV) transmission in the community

Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand.

Moderna to cut mRNA drug substance production at Lonza facility

Unity Software

Short-term investors in Moderna are worried about lower expected vaccine adoption. Unity Software's new fee structure has caused some backlash.

2 Stocks That Sank Hard on Monday

Moderna's coronavirus vaccine revenue is tanking, and it could continue to fall. However, the company has plenty of activity ongoing in the pipeline, with new medicines on the way.

Here Are 15 New Reasons to Be Bullish About Moderna Stock

Advanced Micro Devices

CRISPR Therapeutics

Medtronic

Intellia Therapeutics

NVIDIA

Vertex Pharmaceuticals

Before investing in a trend, it's important to make sure it isn't a fad of the moment and instead has staying power. Artificial intelligence and CRISPR gene editing are two popular trends that could be game-changers down the road.

2 Top Trends to Invest $500 In Right Now

Chewy

Moderna aims to launch 15 new products over the next few years. Vertex Pharmaceuticals is waiting for a regulatory decision an exciting new product.

Looking for Growth? These Companies' Revenue May Skyrocket

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

Biotech stocks are known for their extreme levels of volatility. Moderna, an mRNA specialist, has fallen in dramatic fashion from its all-time high.

Is Moderna Stock a Top Buy?

Alaska Air Group

Etsy

General Motors

Insulet

SolarEdge Technologies

Warner Bros Discovery Inc

The "Magnificent Seven" stocks in the S&P 500 are about to get a run for their money, analysts say.

7 Stocks Will Make You 46% Richer Than 'Magnificent 7,' Analysts

The UK drug regulator said on Friday it has approved an updated COVID-19 vaccine by Moderna , making it the second shot to be used in the country's vaccination campaign this autumn.

UK regulator approves Moderna's updated COVID vaccine

Moderna's coronavirus vaccine sales are on the decline -- but other blockbuster products may be on the way. These products should more than compensate for any lost vaccine sales.

This 1 Number May Completely Change Your Opinion About Moderna

Bristol-Myers

Pfizer

It's been a rough year to invest in pharma stocks. The industry is adjusting to a sector that is less reliant on Covid-19 vaccines and is adapting to the effects of inflation as well as pressure from regulators to cap the price of many drugs.

The 3 Most Undervalued Pharma Stocks to Buy in September 2023

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Moderna (MRNA) Surges 3.2%: Is This an Indication of Further Gains?

The European regulator's advisory panel on Thursday recommended authorizing Moderna's COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant.

EU regulator panel recommends authorizing Moderna's updated COVID shot

The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for autumn/winter 2023 vaccination campaigns Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Spikevax, its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Moderna's updated COVID-19 vaccine for autumn/winter 2023.

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in The European Union

Novavax

BA.2.86 is a new COVID variant health officials have been eyeing lately. But recent reports suggest that it may not be all that concerning.

Why COVID Vaccine Demand Might Not Be That Strong

American Superconductor

BlackBerry

Lithium Americas Corp

Cassava Sciences Inc

Super Micro Computer

SoFi Technologies

Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. In fact, considering GME's continued declines, and AMC's capitulation in recent weeks, you may think that the meme stock phenomenon has completely gone the way of the dodo.

The 7 Best Meme Stocks to Buy Now: September 2023

Moderna, Inc. (NASDAQ:MRNA ) R&D Day and Business Updates September 13, 2023 1:00 PM ET Company Participants Stephane Bancel - CEO Stephen Hoge - President Jackie Miller - SVP, Therapeutic Area Head, Infectious Diseases Darin Edwards - Executive Director, COVID Vaccines Program Leader Raffael Nachbagauer - Program Leader for Influenza Vaccines Arpa Garay - Chief Commercial Officer Kyle Holen - Head of Development, Oncology and Therapeutics Michelle Nguyen - Director of Marketing James Mock - CFO Conference Call Participants Geoff Meacham - BofA Michael Yee - Jefferies Evan Wang - Guggenheim Salveen Richter - Goldman Sachs Gina Wang - Barclays Tyler Van Buren - TD Cowen Hartaj Singh - Oppenheimer Steve Chesney - Redburn Atlantic Stephane Bancel Thank you for those joining us here and thank you for those joining us online today. Before I start, let me just remind you that we'll be making forward-looking statements, and of course, Investing in Moderna entails risk.

Moderna, Inc. (MRNA) R&D Day and Business Updates (Transcript)

Stephane Bancel told Barron's the company won't be defined by its Covic-19 vaccine even as it uses the same technology to develop other vaccines.

'This Is Not a Covid Vaccine Company,' Moderna CEO Says

Moderna (MRNA) was one of the best-performing stock in the S&P 500 as the vaccine maker reported its experimental flu shot met its primary endpoint in a Phase 3 trial.

Moderna Reports Successful Trial of Flu Vaccine, Plans More Treatments Ahead

Shares of Moderna (NASDAQ: MRNA ) — which rose to prominence with its Covid-19 vaccine — are jumping on Wednesday. Disclosing encouraging results for its mRNA-based flu shot, the biotech company may have the opportunity to pivot beyond its Covid vaccine.

Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm

Moderna Inc  (NASDAQ:MRNA) stock is up 6.5% to trade at $112.09 at last check, after a late-stage trial of its flu vaccine induced a stronger immune response against all four A and B strains of the virus in comparison to other flu shots.

Options Bulls Blast Moderna Stock on Vaccine Tailwinds

The CEO of Moderna Inc. (NASDAQ: MRNA) showed optimism for the company in a recent interview for Squawk Box on CNBC, foreseeing between $6 billion to $8 billion in sales in 2023, as their COVID-19 booster got approved by the FDA on September 11.

News for Moderna Stock (MRNA)